Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice

Biochemical Pharmacology

Volumn 70, Issue 3, 2005, Pages 334-342

  Burleigh, Michael E ^a   Babaev, Vladimir R ^a   Patel, Mayur B ^a   Crews, Brenda C ^a   Remmel, Rory P ^c   Morrow, Jason D ^a   Oates, John A ^a   Marnett, Lawrence J ^a   Fazio, Sergio ^a,b   Linton, MacRae F ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aorta; ApoE mice; Atherosclerosis; COX inhibition; Cyclooxygenase; Prostaglandins

Indexed keywords

ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN DERIVATIVE; INDOMETACIN PHENETHYLAMINE; PROSTAGLANDIN SYNTHASE; THROMBOXANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; AORTA SINUS; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; INTERMETHOD COMPARISON; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; INDOMETHACIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOXANES;

EID: 21344447800     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.04.044     Document Type: Article

References (39)

1. R. Ross Atherosclerosis - an inflammatory disease New Eng J Med 340 1999 115 126
2. R. DuBois, S. Abramson, L. Crofford, R.A. Gupta, L. Simon, and L. Van De Putte Cyclooxygenase in biology and disease FASEB J 12 1998 1063 1073
3. J.R. Vane, Y.S. Bakhle, and R.M. Botting Cyclooxygenase 1 and 2 Ann Rev Phamacol Toxicol 38 1998 97 120
4. C.S. Baker, R.J. Hall, T.J. Evans, A. Pomerance, J. Maclouf, and C. Creminon Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages Arterioscler Thromb Vasc Biol 19 3 1999 646 655
5. U. Schonbeck, G.K. Sukhova, P. Graber, S. Coulter, and P. Libby Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am J Pathol 155 1999 1281 1291
6. M.E. Burleigh, V.R. Babaev, J.A. Oates, R.C. Harris, S. Gautam, and D. Riendeau Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice Circulation 105 2002 1816 1823
7. C.H. Hennekens, M.L. Dyken, and V. Fuster Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 96 1997 2751 2753
8. Y. Cheng, S.C. Austin, B. Rocca, B.H. Koller, T.M. Coffman, and T. Grosser Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 5567 2002 539 541
9. O.A. Belton, A. Duffy, S. Toomey, and D.J. Fitzgerald Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis Circulation 108 2003 3017 3023
10. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis New Eng J Med 343 2000 1520 1528
11. D. Mukherjee, S.E. Nissen, and E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors J Am Med Assoc 286 2001 954 959
12. R. Chenevard, D. Hurlimann, M. Bechir, F. Enseleit, L. Spieker, and M. Hermann Selective COX-2 inhibition improves endothelial function in coronary artery disease Circulation 107 3 2003 405 409
13. F. Cipollone, C. Prontera, B. Pini, M. Marini, M. Fazia, and D. De Cesare Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability Circulation 104 8 2001 921 927
14. F. Cipollone, E. Toniato, S. Martinotti, M. Fazia, A. Lezzi, and C. Cuccurullo Identification of new elements of plaque stability study G, a polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke J Am Med Assoc 291 2004 2221 2228
15. J.M. Bailey, and J. Butler Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation Atherosclerosis 17 3 1973 515 522
16. D. Pratico, C. Tillmann, Z.B. Zhang, H. Li, and G.A. FitzGerald Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice Proc Natl Acad Sci USA 98 2001 3358 3363
17. M. Olesen, E. Kwong, A. Meztli, F. Kontny, I. Seljeflot, and H. Arnesen No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice Scand Cardiovasc J 36 2002 362 367
18. F. Bea, E. Blessing, B.J. Bennett, C.C. Kuo, L.A. Campbell, and J. Kreuzer Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis Cardiovasc Res 60 2003 198 204
19. D. Rott, J. Zhu, M.S. Burnett, Y.F. Zhou, A. Zalles-Ganley, and J. Ogunmakinwa Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice J Am Coll Cardiol 41 2003 1812 1819
20. A.S. Kalgutkar, B.C. Crews, S.W. Rowlinson, A.B. Marnett, K.R. Kozak, and R.P. Remmel Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors Proc Natl Acad Sci USA 97 2 2000 925 930
21. M.F. Linton, J.B. Atkinson, and S. Fazio Prevention of atherosclerosis in apoE deficient mice by bone marrow transplantation Science 267 1995 1034 1037
22. L.J. Marnett, T.L. Wright, B.C. Crews, S.R. Tannenbaum, and J.D. Morrow Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase J Biol Chem 275 2000 13427 13430
23. J. Reese, B.C. Paria, N. Brown, X. Zhao, J.D. Morrow, and S.K. Dey Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse Proc Natl Acad Sci USA 97 17 2000 9759 9764
24. V.R. Babaev, M.B. Patel, C.F. Semenkovich, S. Fazio, and M.F. Linton Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice J Biol Chem 275 2000 26293 26299
25. B. Paigen, P. Holmes, D. Mitchell, and D. Albee Comparison of atherosclerotic lesions and HDL-lipid levels in male, females, and testosterone-treated female mice from strains C57BL/6, BALB/c and C3H Atherosclerosis 68 1987 215 221
26. R.L. Czervionke, J.C. Hoak, and G.L. Fry Effect of aspirin on thrombin-induced adherence of platelets to cultured cells from the blood vessel wall J Clin Invest 62 4 1978 847 856
27. G.A. FitzGerald, J.A. Oates, J. Hawiger, R.L. Maas, L.J. Roberts 2nd, and J.A. Lawson Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man J Clin Invest 71 3 1983 676 688
28. K.M. Egan, M. Wang, M.B. Lucitt, A.M. Zukas, E. Pure, and J.A. Lawson Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism Circulation 111 3 2005 334 342
29. A.J. Cayatte, Y. Du, J. Oliver-Krasinski, G. Lavielle, T.J. Verbeuren, and R.A. Cohen The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 1724 1728
30. A. Paul, L. Calleja, J. Camps, J. Osada, E. Vilella, and N. Ferre The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice Life Sci 68 4 2000 457 465
31. T. Cyrus, S. Sung, L. Zhao, C.D. Funk, S. Tang, and D. Pratico Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice Circulation 106 10 2002 1282 1287
32. -/- mice administered an ASBT inhibitor or a selective COX-2 inhibitor Arterioscler Thromb Vasc Biol 22 2002 P409
33. S.B. Joseph, A. Castrillo, B.A. Laffitte, D.J. Mangelsdorf, and P. Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors Nat Med 9 2003 213 219
34. D. Kothapalli, I. Fuki, K. Ali, S. Stewart, L. Zhao, and R. Yahil Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation J Clin Invest 113 4 2004 609 618
35. W.A. Ray, C.M. Stein, J.R. Daugherty, K. Hall, P.G. Arbogast, and M.R. Griffin COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease Lancet 360 2002 1071 1073
36. D. Solomon, S. Schneeweiss, R. Glynn, Y. Kiyota, R. Levin, and H. Mogun Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 109 2004 2068 2073
37. M.A. Konstam, M.R. Weir, A. Reicin, D. Shapiro, R.S. Sperling, and E. Barr Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib Circulation 104 2001 2280 2288
38. A.S. Reicin, D. Shapiro, R.S. Sperling, E. Barr, and Q. Yu Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone) Am J Cardiol 89 2002 204 209
39. F. Silverstein, G. Faich, J. Goldstein, L. Simon, T. Pincus, and A. Whelton Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study J Am Med Assoc 284 2000 1247 1255